Allergan Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (57)

Latest Posts

About This Stock More About This Stock
Allergan (AGN) Beats Q3 Earnings, Sales In Line, Stock Up
Article By: Zacks Investment Research
Wednesday, November 1, 2017 11:07 AM EST
Allergan’s third-quarter earnings of $4.15 per share were above our consensus estimate of $4.06 per share.
In this article: AGN
Is Allergan Stock Finally Going To Reward Shareholders?
Article By: Modest Money
Thursday, October 19, 2017 12:31 PM EST
Allergan Stock has been a painful ride for investors. Starting last year when the proposed merger with Pfizer fell through, Allergan stock has fallen.
In this article: AGN
Allergan Says Mohawks Bought Restasis Patents With Immunity Promise
Article By: Shock Exchange
Friday, October 13, 2017 10:36 AM EST
AGN the Mohawks brought Restasis patents with a promise of immunity. I estimate the patents are worth $14B. The patent judge want to determine if the deal was a sham.
In this article: AGN Also: MYL, TEVA
Senator Thwarts Allergan's Patent Transfer, Inflaming The Mohawks
Article By: Shock Exchange
Friday, October 6, 2017 5:51 PM EST
Senator Claire McCaskill drafted a bill to thwart the transfer of AGN's Restasis patents to the Mohawk Tribe. Next steps could be to push for Medicare Part D access for SHPG's Xiidra and prioritize clinical stage drugs from RGRX or ALDX.
In this article: AGN Also: SHPG, RGRX, ALDX, TEVA, IMMY
Pharma Stock Roundup: Mylan Up, Teva Down On Copaxone News, Lawmakers Question Allergan Deal
Article By: Arpita Dutt
Friday, October 6, 2017 10:31 AM EST
While Mylan and Teva were in the news related to the FDA approval of Mylan’s generic versions of Teva’s top-selling branded drug, Copaxone, Allergan is under fire for its agreement with the Saint Regis Mohawk Tribe for Restasis.
In this article: AGN, TEVA, MYL Also: NVO, SNY, LLY, GSK


Latest Tweets for $AGN

No tweets yet!


Valeant Edges Up 15% After Announcing That It Will Acquire Salix
Terry Caruso 2/24/2015 8:20:44 PM

You said the company tried to acquire Allergan but the deal fell through because Valeant didn't like it's large R&D program. If true, why did it try to acquire $AGN in the first place?

1 to 1 of 1 comments